high purity hot sale 1,2-Dihexanoyl-sn-glycero-3-PC 99% high quality see COA KANBEI
34506-67-7
Industrial Grade
99%
SHANGHAI
KANBEI
25kg drum
2023-12-31
PVC resin,pvc paste resin,melamine
-
Product Description
-
Seller Information
-
DescriptionBasic Info
-
Product Name:
1,2-DIHEXANOYL-SN-GLYCERO-3-PHOSPHOCHOLINE
Other Name:DHPC;L-ALPHA-PHOSPHATIDYLCHOLINE, DICAPROYL (C6:0);1,2-DIHEXANOYL-SN-GLYCERO-3-PHOSPHATIDYLCHOLINE;1,2-DIHEXANOYL-SN-GLYCERO-3-PHOSPHOCHOLINE;1,2-DICAPROYL-SN-GLYCERO-3-PHOSPHOCHOLINE;06:0 PC;L-A-PHOSPHATIDYLCHOLINE, DICAPROYL;dihexanoyl-l-a-phosphatidylcholine
CAS No.:34506-67-7
Molecular Formula:C20H40NO8P
Molecular Weight:453.51
Categories:
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
PVC resin,pvc paste resin,melamine
-
Location:
Room 405, Unit 2, Building 1, Taiji Mansion, No. 38, Nanyang Road, Jinshui District, Zhengzhou City, Henan Province
-
Payment Terms:
TT against copy of documents,L/C
-
Average lead Time:
90
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
11-50
-
Year of Establishment:
2022
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product